You are here

  • Home
  • Archive
  • Volume 14, Issue 6
  • Rosiglitazone was non-inferior to metformin plus sulphonylurea for CV events but increased risk of HF and fractures in type 2 diabetes

Article Text

Article menu
Download PDFPDF
Therapeutics
Rosiglitazone was non-inferior to metformin plus sulphonylurea for CV events but increased risk of HF and fractures in type 2 diabetes

https://doi.org/10.1136/ebm.14.6.168

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Study design

    Design:

    randomised controlled trial (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes [RECORD]). ClinicalTrials.gov NCT00379769.

    Allocation:

    concealed.*

    Blinding:

    blinded (outcome adjudication committee).*

    Study question

    Setting:

    364 centres in 25 countries in Europe and Australasia.

    Patients:

    4458 patients 40–75 years of age (mean age 58 y, 52% men) who had type 2 diabetes, body mass index >25 (mean 31) kg/m2, and haemoglobin (Hb) A1c concentration >7.0% to 9.0% (mean 7.9%) on maximum doses of metformin (MFN) or sulphonylurea (SFU). Exclusion criteria included hospital admission for a major cardiovascular (CV) event in ⩽3 months, planned CV intervention, and heart failure (HF).

    Intervention:

    rosiglitazone (RGZ), 4 mg/day, plus MFN or SFU, with starting doses determined by local practice (n = 2220); or MFN plus SFU (control) (n = 2227). Drug doses …

    View Full Text

    Footnotes

    • Source of funding GlaxoSmithKline.